Stem cell transplant for Waldenström macroglobulinemia: An underutilized technique

Bone Marrow Transplantation

Volumn 47, Issue 9, 2012, Pages 1147-1153

  Gertz, M A ^a   Reeder, C B ^b   Kyle, R A ^a   Ansell, S M ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

allogeneic transplant; autologous transplant; lymphoplasmacytic lymphoma; non Hodgkin lymphoma; stem cell transplant; Waldenstr m macroglobulinemia

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION;

HUMANS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84865975384     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.175     Document Type: Review

References (57)

1. Waldenström J. Forty years with the gamma globulins. Scand J Immunol 1987; 25: 211-218.
2. Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol 2007; 138: 700-720.
3. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133: 158-164.
4. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85: 824-833.
5. Vitolo U, Ferreri AJ, Montoto S. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. Crit Rev Oncol Hematol 2008; 67: 172-185.
6. Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC et al. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 2007; 136: 80-86. (Pubitemid 44912591)
7. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004; 45: 2047-2055. (Pubitemid 39232853)
8. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ et al. Waldenströ m's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108: 737-742. (Pubitemid 30304504)
9. Yang K, Tan J, Wu T. Alkylating agents for Waldenstrom's macroglobulinaemia. Cochrane Database Syst Rev 2009, CD006719.
10. Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 5: 273-277. (Pubitemid 40614242)
11. Ioakimidis L, Patterson CJ, Hunter ZR, Soumerai JD, Manning RJ, Turnbull B et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenströ m's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9: 62-66.
12. Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SWOG 9003). Semin Oncol 2003; 30: 220-225. (Pubitemid 36506313)
13. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 243-247. (Pubitemid 36506318)
14. Agathocleous A, Rohatiner A, Rule S, Hunter H, Kerr JP, Neeson SM et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol 2010; 151: 346-353.
15. Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol 2010; 85: 670-674.
16. Merchionne F, Procaccio P, Dammacco F. Waldenströ m's macroglobulinemia: an overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center. Crit Rev Oncol Hematol (e-pub ahead of print 28 October 2010).
17. Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28: 1408-1414.
18. Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010; 16: 1033-1041.
19. Leleu X, Gay J, Roccaro AM, Moreau AS, Poulain S, Dulery R et al. Update on therapeutic options in Waldenström macroglobulinemia. Eur J Haematol 2009; 82: 1-12.
20. Garcia-Sanz R, Ocio EM. Novel treatment regimens for Waldenströ m's macroglobulinemia. Expert Rev Hematol 2010; 3: 339-350.
21. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27: 250-255.
22. Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010; 24: 2056-2062.
23. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 2011; 86: 23-31.
24. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010; 51: 1178-1187.
25. Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF et al. Geneexpression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006; 108: 2755-2763.
26. Gribben JG. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2009; 15 (1 Suppl): 53-58.
27. Tam CS, Khouri I. The role of stem cell transplantation in the management of chronic lymphocytic leukaemia. Hematol Oncol 2009; 27: 53-60.
28. Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010; 24: 1769-1778.
29. Chang H, Samiee S, Li D, Patterson B, Chen CI, Stewart AK. Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single center study of 22. cases. Leukemia 2004; 18: 1160-1162. Erratum in: Leukemia 2004; 18: 1564. 22. cases. Leukemia 2004; 18: 1160-1162. Erratum in: Leukemia 2004; 18: 1564. (Pubitemid 38786983)
30. Schmid JR, Kiely JM, Tauxe WN, Owen Jr CA. In vitro DNA and RNA synthesis in human bone marrow cells: a study of 12 normal subjects and 12 patients with lymphoplasmocytic disorders. Blood 1966; 27: 310-318.
31. Latreille J, Barlogie B, Johnston D, Drewinko B, Alexanian R. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 1982; 59: 43-51. (Pubitemid 12162344)
32. Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM et al. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol 2010; 3: 38.
33. Nichols GL, Skerrett DL. Peripheral blood stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia. Stem Cells Dev 2005; 14: 3-35.
34. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009; 27: 120-126.
35. Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010; 150: 647-662.
36. Trotman J, Presgrave P, Kwan Y, Tiley C, Estell J, Watson AM et al. Consensus guidelines for 'rainy day' autologous stem cell harvests in New South Wales. Intern Med J 2008; 38: 229-234. (Pubitemid 351465453)
37. Caravita T, Siniscalchi A, Tendas A, Cupelli L, Dentamaro T, Natale G et al. High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia. Bone Marrow Transplant 2009; 43: 587-588.
38. Yang L, Wen B, Li H, Yang M, Jin Y, Yang S et al. Autologous peripheral blood stem cell transplantation for Waldenstrom's macroglobulinemia. Bone Marrow Transplant 1999; 24: 929-930. (Pubitemid 29500357)
39. Desikan R, Dhodapkar M, Siegel D, Fassas A, Singh J, Singhal S et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia. Br J Haematol 1999; 105: 993-996. (Pubitemid 29309108)
40. Anagnostopoulos A, Dimopoulos MA, Aleman A, Weber D, Alexanian R, Champlin R et al. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant 2001; 27: 1027-1029. (Pubitemid 32591184)
41. Munshi NC, Barlogie B. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 282-285. (Pubitemid 36506326)
42. Fassas A, Barlogie B, Ward S, Rasmussen E, van Rhee F, Zangari M et al. High-dose treatment (HDT) and autologous stem cell transplant (ASCT) in Waldenstrom's macroglobulinemia (WM) patients (pts): a single center experience [abstract]. J Clin Oncol 2005; 23 (16S): 6661.
43. Anagnostopoulos A, Giralt S. Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM). Bone Marrow Transplant 2002; 29: 943-947. (Pubitemid 34845947)
44. Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N et al. Transplantation in Waldenstrom's macroglobulinemia: the French experience. Semin Oncol 2003; 30: 291-296. (Pubitemid 36506328)
45. Anagnostopoulos A, Hari PN, Perez WS, Ballen K, Bashey A, Bredeson CN et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845-854. (Pubitemid 44096738)
46. Kyriakou C, Canals C, Taghipour G, Gisselbrecht C, Mazza P, Kazmi M et al. Autologous stem cell transplantation (ASCT) for patients with Waldenstrom's macroglobulinaemia: an analysis of 201 cases from the European Bone Marrow Transplant Registry (EBMT) [abstract]. Haematologica 2007; 92 (S2): 228.
47. Dhedin N, Tabrizi R, Bulabois PE, Le Gouill S, Coiteux V, Dartigeas C et al. Hematopoietic stem cell transplantation (HSCT) in Waldenstrom macroglobulinemia (WM): update of the French experience in 54 cases. Haematologica 2007; 92(S):228
48. Gilleece MH, Pearce R, Linch DC, Wilson M, Towlson K, Mackinnon S et al. The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology 2008; 13: 119-127.
49. Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 2227-2232.
50. Martino R, Shah A, Romero P, Brunet S, Sierra J, Domingo-Albos A et al. Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia. Bone Marrow Transplant 1999; 23: 747-749. (Pubitemid 29176544)
51. Ueda T, Hatanaka K, Kosugi S, Kishino BI, Tamaki T. Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinemia with severe pancytopenia. Bone Marrow Transplant 2001; 28: 609-611. (Pubitemid 32976362)
52. Stakiw J, Kim DH, Kuruvilla J, Gupta V, Messner H, Lipton JH. Evidence of graftversus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience. Bone Marrow Transplant 2007; 40: 369-372. (Pubitemid 47202422)
53. Meniane JC, El-Cheikh J, Faucher C, Furst S, Bouabdallah R, Blaise D et al. Longterm graft-versus-Waldenström macroglobulinemia effect following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 40: 175-177. (Pubitemid 47046216)
54. Yamamoto R, Takaori-Kondo A, Kanda J, Imada K, Ichinohe T, Ishikawa T et al. Durable remission of large B-cell lymphoma transformed from lymphoplasmacytic lymphoma/Waldenström macroglobulinemia successfully treated with sequential immunochemotherapy followed by reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 591-593. (Pubitemid 351472154)
55. Anagnostopoulos A, Aleman A, Giralt S. Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: review of the literature and future directions. Semin Oncol 2003; 30: 286-290. (Pubitemid 36506327)
56. Garnier A, Robin M, Larosa F, Golmard JL, Le Gouill S, Coiteux V et al. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia: results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica 2010; 95: 950-955.
57. Kyriakou C, Canals C, Cornelissen JJ, Socie G, Willemze R, Ifrah N et al. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 4926-4934.